154 related articles for article (PubMed ID: 21711228)
1. Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma.
Iurescia S; Fioretti D; Fazio VM; Rinaldi M
Curr Gene Ther; 2011 Oct; 11(5):414-22. PubMed ID: 21711228
[TBL] [Abstract][Full Text] [Related]
2. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
3. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model.
Rinaldi M; Fioretti D; Iurescia S; Signori E; Pierimarchi P; Seripa D; Tonon G; Fazio VM
Biochem Biophys Res Commun; 2008 May; 370(2):279-84. PubMed ID: 18364239
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
7. Antibodies designed as effective cancer vaccines.
Metheringham RL; Pudney VA; Gunn B; Towey M; Spendlove I; Durrant LG
MAbs; 2009; 1(1):71-85. PubMed ID: 20046577
[TBL] [Abstract][Full Text] [Related]
8. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
Singh G; Parker S; Hobart P
Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
[TBL] [Abstract][Full Text] [Related]
9. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.
Iurescia S; Fioretti D; Pierimarchi P; Signori E; Zonfrillo M; Tonon G; Fazio VM; Rinaldi M
J Biomed Biotechnol; 2010; 2010():316069. PubMed ID: 20445751
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
11. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
Cha SC; Qin H; Sakamaki I; Kwak L
Methods Mol Biol; 2014; 1139():289-303. PubMed ID: 24619688
[TBL] [Abstract][Full Text] [Related]
12. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
Baskar S; Kobrin CB; Kwak LW
J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
[TBL] [Abstract][Full Text] [Related]
13. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
Patel KG; Ng PP; Levy S; Levy R; Swartz JR
Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
[TBL] [Abstract][Full Text] [Related]
14. Vaccines for lymphomas: idiotype vaccines and beyond.
Houot R; Levy R
Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
[TBL] [Abstract][Full Text] [Related]
15. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
Armstrong AC; Cheadle EJ; Hawkins RE
BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccination against cancer antigens.
Stevenson FK; Zhu D; Spellerberg MB; Rice J; King CA; Thompsett AR; Sahota SS; Hamblin TJ
Ernst Schering Res Found Workshop; 2000; (30):119-36. PubMed ID: 10943320
[No Abstract] [Full Text] [Related]
18. [Experimental study on TCRbeta idiotypic antigenic determinants DNA vaccine to induce anti-lymphoma antibodies].
Zhang Y; Zhu P; Shi Y; Liu J; Pu D; Cao X; Zhu Q; Wang Y; Ma M; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):68-72. PubMed ID: 12015073
[TBL] [Abstract][Full Text] [Related]
19. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
20. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
